Developing a Regulatory Strategy for Monoclonal Antibodies

Gore, Mugdha; Hansen, Suzanne K.; Miller, Loren L.

doi:10.1177/009286159603000129

Cited by 4 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radioisotopes include Iodine-131, Indium-11 1, Yttrium-90, Phosphorus-34, and Rhenium-186. The development of regulatory strategies for monoclonal antibodies has been described elsewhere (1). Gene therapy is the newest and most novel method of drug disposition modulation.…”

Section: Drug Disposition Modulatorsmentioning

confidence: 99%

Regulatory Strategies for the Development of Adjunctive Cancer Chemotherapies

Hansen¹,

Miller

1997

Drug Information J

Self Cite

View full text Add to dashboard Cite

A key to obtaining timely approval of a new drug application for an adjunctive chernotherapy for cancer is the early development of a well-researched overall regulatory strategy. That strategy should contain an effective and detailed development plan, from preclinical assessments to the pivotal clinical trials design, always with the jinal desired labeling as the goal. This plan should include a carefully chosen and well-defined indication; established endpoints with scientific validity and clinical meaning that can pass regulatory scrutiny; adequate characterization of the patient population for the clinical trials; coordination of comparison studies with a currently marketed product approved for the same indication; plans for preclinical and clinical studies to sufficiently characterize toxicity; and upfront design of the data analyses such that subpopulations of patients may be evaluated on predefined safety and efficacy variables. The use of established scientific methodology in the construction of an overall development plan early in the evolution of a drug product can lead to a cost-and time-effective drug development program and a successful review process.

show abstract

Section: Drug Disposition Modulatorsmentioning

confidence: 99%